2014.

• Dec.26.2014

  Bristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from the U.S. Food and Drug Administration(131 KB)

• Dec.19.2014

  ONO AND GILEAD ANNOUNCE EXCLUSIVE LICENSE AGREEMENT TO DEVELOP BTK INHIBITOR, ONO-4059, FOR THE TREATMENT OF B-CELL MALIGNANCIES AND OTHER DISEASES(35 KB)

• Dec.11.2014

  ONO Establishes a Local Subsidiary in Taiwan(58 KB)

• Dec.10.2014

  Opdivo (nivolumab) Demonstrates High Overall Response Rate of 87% for Treatment of Relapsed or Refractory Hodgkin Lymphoma(115 KB)

• Dec.10.2014

  ONO PHARMACEUTICAL, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors(36 KB)

• Nov.19.2014

  Study Comparing Opdivo (nivolumab) to Chemotherapy in Treatment Naive Advanced Melanoma Patients Marks First PD-1 Immune Checkpoint Inhibitor to Demonstrate a Survival Benefit in a Phase 3 Trial(86 KB)

• Nov.05.2014

  Announcement on Financial Results for FY2014 2Q

• Nov.05.2014

  ONO files an application for RIVASTACH® PATCH for adding dosage and administration in Japan(28 KB)

• Oct.31.2014

  Helsinn Group, Switzerland, announced new data on Fatigue from Phase III Trial (ROMANA 1) of Anamorelin/ONO-7643 in patients with Cancer Anorexia-Cachexia Syndrome (CACS) associated with Non-Small Cell Lung Cancer at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology(106 KB)

• Oct.31.2014

  Phase 2 Objective Response Rates and Survival Data for Opdivo (nivolumab) in Heavily Pre-treated Advanced Squamous Cell Non-Small Cell Lung Cancer to be Presented at the 2014 Chicago Multidisciplinary Symposium on Thoracic Oncology(111 KB)

• Oct.29.2014

  Establishment of GPCR Consortium, a New International Partnership, to Advance Structural Information about G-protein Coupled Receptors(341 KB)

• Oct.08.2014

  Revisions of Consolidated Financial Forecasts(19 KB)

• Oct.07.2014

  Approval for the Stability-Improved Formulation of Limaprost, an Oral Prostaglandin E1 Analogue in Japan(36 KB)

• Oct.03.2014

  European Medicines Agency Validates the Marketing Authorization Application for Opdivo (Nivolumab) in Non-Small Cell Lung Cancer(77 KB)

• Oct.02.2014

  Bristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo (nivolumab) in the U.S. and European Union(73 KB)

• Sep.30.2014

  Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy® (ipilimumab) Presented at the ESMO 2014 Congress(136 KB)

• Sep.29.2014

  Helsinn Group, Switzerland, announced the results of Phase III Trials (ROMANA 1 and ROMANA 2) of Anamorelin/ONO-7643 in patients with Cancer Anorexia-Cachexia Syndrome (CACS) associated with Non-Small Cell Lung Cancer(144 KB)

• Sep.02.2014

  Human Anti-human PD-1 Monoclonal Antibody OPDIVO® Intravenous Infusion 20 mg/100 mg launches in Japan for Treatment of Unresectable Melanoma(179 KB)

• Aug.20.2014

  Announcement of top-line results from Phase 3 FOCUS Trial of Carfilzomib (ONO-7057), a proteasome inhibitor, in patients with relapsed and advanced refractory multiple myeloma(80 KB)

• Aug.11.2014

  Phase 3 ASPIRE Trial of Carfilzomib (ONO-7057), a proteasome inhibitor, in patients with relapsed multiple myeloma met primary endpoint (Progression-free survival)(190 KB)

• Aug.04.2014

  Announcement on Financial Results for FY2014 1Q

• Jul.28.2014

  Ono and Meiji Seika Pharma enter into an agreement on development and commercialization of Limaprost in Thailand and Indonesia(26 KB)

• Jul.24.2014

  ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan(86 KB)

• Jul.11.2014

  Human Anti-human PD-1 Monoclonal Antibody OPDIVO® Bristol-Myers Squibb plans for Third Quarter Submission of a Biologics License Application for Previously Treated Advanced Melanoma(232 KB)

• Jul.09.2014

  Ono Enters into the Collaboration Agreement with the University of Tokyo regarding Access to Ono's Compound Library(30 KB)

• Jul.04.2014

  Human Anti-human PD-1 Monoclonal Antibody "OPDIVO® Intravenous Infusion 20 mg/100 mg" Receives Manufacturing and Marketing Approval in Japan for the Treatment of Unresectable Melanoma(53 KB)

• Jun.25.2014

  Fully Human Anti-PD-1 Antibody Nivolumab ("ONO-4538/BMS-936558") Demonstrates Superior Overall Survival Compared to Dacarbazine in Phase 3 First-Line Melanoma Study (CheckMate -066)(177 KB)

• Jun.17.2014

  Termination of the license agreement for ONO-4641 mutually agreed by Ono and Merck(40 KB)

• Jun.03.2014

  Fully Human Anti-PD-1 Antibody “ONO-4538/BMS-936558”Results from Phase 1 Study in Patients with Melanoma Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO)(69 KB)

• May.23.2014

  FORXIGA® launches in Japan for the treatment of Type 2 diabetes(100 KB)

• May.23.2014

  Glactiv® has obtained the approval of the partial change in the indications of "type 2 diabetes"(29 KB)

• May.13.2014

  Announcement on Financial Results for FY2013

• May.13.2014

  Announcement on Candidates of Members of the Board of Directors and Corporate Officers(39 KB)

• May.13.2014

  Position and policies concerning the reduction of the minimum investment unit(21 KB)

• Apr.30.2014

  Discontinuation of the license agreement for a new therapeutic agent for thrombocytopenia(16 KB)

• Mar.24.2014

  FORXIGA® (dapagliflozin) receives regulatory approval in Japan for the treatment of Type 2 diabetes(94 KB)

• Mar.06.2014

  ONO establishes an innovative research network called "Orientem Innovation" together with Tohoku University & The University of Tokyo(166 KB)

• Feb.04.2014

  Announcement on Financial Results for FY2013 3Q

• Jan.17.2014

  Annoucement on CSR Report 2013